GRN-1201 With Pembrolizumab in Subjects With Metastatic PD-L1+ NSCLC

Clinical trial NCT03417882 · TERMINATED

Trial details

NCT number: NCT03417882
Sponsor: BrightPath Biotherapeutics
Status: TERMINATED
Phase: Phase 2
Study type: INTERVENTIONAL

Metastatic NSCLC

Start date: 2019-01-03
Primary completion: 2022-12-05
Enrollment: 20

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.